LobbyingNational Brain Tumor Society on Behalf of Deadliest Cancers Coalition lobbying by quarter
National Brain Tumor Society on Behalf of Deadliest Cancers Coalition's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q1 2026; the issues it reports most are Budget/Appropriations and Health Issues.
National Brain Tumor Society on Behalf of Deadliest Cancers Coalition
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 3 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q1 2026
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$0 · 2 reports
- Health issues$0 · 1 reports
- Medicare and Medicaid$0 · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| MGD Strategies | $0 | 2 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/19for Q2 | MGD Strategies | Under $5,000 |
| 08/19for Q1 | MGD Strategies | Under $5,000 |
| 08/12for Q3 | MGD Strategies | Under $5,000 |